- Home
- ACET vs RNTX Comparison
ACET vs RNTX Comparison
Compare ACET & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- RNTX
- Stock Information
- Founded
- ACET 1947
- RNTX 2001
- Country
- ACET United States
- RNTX United States
- Employees
- ACET N/A
- RNTX N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- RNTX Health Care
- Exchange
- ACET Nasdaq
- RNTX Nasdaq
- Market Cap
- ACET 44.4M
- RNTX 44.2M
- IPO Year
- ACET N/A
- RNTX N/A
- Fundamental
- Price
- ACET $0.59
- RNTX $1.91
- Analyst Decision
- ACET Buy
- RNTX
- Analyst Count
- ACET 6
- RNTX 0
- Target Price
- ACET $6.00
- RNTX N/A
- AVG Volume (30 Days)
- ACET 509.0K
- RNTX 32.6K
- Earning Date
- ACET 05-13-2025
- RNTX 04-07-2025
- Dividend Yield
- ACET N/A
- RNTX N/A
- EPS Growth
- ACET N/A
- RNTX N/A
- EPS
- ACET N/A
- RNTX N/A
- Revenue
- ACET N/A
- RNTX N/A
- Revenue This Year
- ACET N/A
- RNTX N/A
- Revenue Next Year
- ACET N/A
- RNTX N/A
- P/E Ratio
- ACET N/A
- RNTX N/A
- Revenue Growth
- ACET N/A
- RNTX N/A
- 52 Week Low
- ACET $0.45
- RNTX $1.35
- 52 Week High
- ACET $1.87
- RNTX $5.19
- Technical
- Relative Strength Index (RSI)
- ACET 42.27
- RNTX N/A
- Support Level
- ACET $0.51
- RNTX N/A
- Resistance Level
- ACET $0.62
- RNTX N/A
- Average True Range (ATR)
- ACET 0.06
- RNTX 0.00
- MACD
- ACET 0.01
- RNTX 0.00
- Stochastic Oscillator
- ACET 63.38
- RNTX 0.00
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.